Evidence map›Paper›PMID 29983898›Full record

ArticleOncotarget2018

Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment.

Hajer Ziouziou, Claudia Andrieu, Erik Laurini, Sara Karaki, Maurizio Fermeglia, Ridha Oueslati, David Taieb, Michel Camplo, Olivier Siri, Sabrina Pricl and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Hajer ZiouziouInserm, UMR1068, CRCM, Marseille, France.
Claudia AndrieuInserm, UMR1068, CRCM, Marseille, France.
Erik LauriniMolecular Simulation Engineering (MOSE) Laboratory, DEA, University of Trieste, Trieste, Italy.
Sara KarakiInserm, UMR1068, CRCM, Marseille, France.
Maurizio FermegliaMolecular Simulation Engineering (MOSE) Laboratory, DEA, University of Trieste, Trieste, Italy.
Ridha OueslatiUnit of Immunology Microbiology Environmental and Carcinogenesis (IMEC), Science Faculty of Bizerte, University of Carthage, Bizerte, Tunisia.
David TaiebInserm, UMR1068, CRCM, Marseille, France.
Michel CamploNational Interuniversity Consortium for Material Science and Technology (INSTM), Research Unit MOSE-DEA, University of Trieste, Trieste, Italy.
Olivier SiriAix-Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille, UMR 7325, Marseille, France.
Sabrina PriclMolecular Simulation Engineering (MOSE) Laboratory, DEA, University of Trieste, Trieste, Italy.
Maria KatsogiannouInserm, UMR1068, CRCM, Marseille, France.
Palma RocchiInserm, UMR1068, CRCM, Marseille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.20469.].

Identifiers

PMID29983898
PMCPMC6033366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.